Condition: Hepatocellular Carcinoma (HCC) · Radioembolization · Sponsor: Seoul National University Hospital
At four major centers in Korea, patients with hepatocellular carcinoma (HCC) that exceed the up-to-7 criteria yet remain locally confined will undergo ablative radioembolization using Yttrium-90 glass microspheres, guided by a standardized dosimetry method. Their treatment response, survival outcomes, and adverse events will be monitored for two years following the procedure.
This description comes directly from the study's public registry record.
Hyun Hee Lee · +82 220724177 · redlion55@snu.ac.kr
Mina Lee · mina.lee@bsci.com
Always discuss trial participation with your own doctor first.
| National Cancer Center | Ilsan, Gyeonggi-do, South Korea | Recruiting |
| Seoul National University Hospital | Seoul, South Korea | Recruiting |
| Severance Hospital | Seoul, South Korea | Recruiting |
| Samsung Medical Center | Seoul, South Korea | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06773845